Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a **topical combination anesthetic** consisting of **lidocaine**, **prilocaine**, and **tetracaine**, used for local dermal anesthesia. All three agents are local anesthetics that act primarily by blocking sodium ion channels in neuronal membranes, thereby inhibiting nerve impulse conduction and producing a reversible loss of sensation in the application area. Lidocaine and prilocaine are amide-type local anesthetics, while tetracaine is an ester-type. The combination is used to increase the efficacy and duration of topical anesthesia, most often prior to procedures such as venipuncture, minor dermatological interventions, or management of pain related to medical devices. In clinical studies, the combined preparation has demonstrated more effective prevention of procedure-induced pain, agitation, and reflexes (such as coughing during tracheal extubation) compared to any component alone[1][4][17]. Lidocaine, prilocaine, and tetracaine act by binding to and inhibiting "Sodium channel protein type 1 subunit alpha" (Nav1.1), and possibly other voltage-gated sodium channels, resulting in reduced neuronal excitability.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lidocaine + prilocaine + tetracaine.